Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05732831 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
A Phase 1 study of Locally Advanced Solid Tumor, sponsored by Tango Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 225
- Enrollment target
- 20
- Study locations
NCT05732831: Recruiting Phase 1 study of Locally Advanced Solid Tumor, sponsored by Tango Therapeutics.
NCT05732831 is a Phase 1 study of Locally Advanced Solid Tumor that is actively recruiting participants, run by Tango Therapeutics. The registered enrollment target is 225 participants, roughly in line with the 224-participant average among 13 other Locally Advanced Solid Tumor trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05732831, a Phase 1 study of Locally Advanced Solid Tumor, is actively recruiting participants, sponsored by Tango Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 225 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Primary Outcome
To determine the maximum tolerated dose (MTD) of TNG462 when administered as a single agent and in combination with pembrolizumab
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG TNG462
Study Locations (20)
Other
- CHU de Brest - Brest
- Centre Berard Leon - Lyon
- Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS - Saint-Herblain
- Institute Gustav Roussy - Villejuif
Illinois
- University Chicago Medicine - Chicago
- Carle Cancer Center - Urbana
- Midwestern Regional Medical Center, City of Hope Chicago - Zion
Florida
- Florida Cancer Specialists & Research Institute - Lake Mary
- Sylvester Comprehensive Cancer Center - Miami
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
California
- Stanford University - Palo Alto
Colorado
- Grand Valley Oncology - Grand Junction
Michigan
- Henry Ford Cancer Center - Detroit
New York
- New York University Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2023-05-26 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What NCT05732831 shows while recruiting
NCT05732831 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 224-participant average among 13 other Locally Advanced Solid Tumor trials with a reported enrollment target.
The record links to 1 condition, with Locally Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05732831 names 20 study sites across 13 states, led by Other, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT05732831 about?
NCT05732831 is a clinical study titled "Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors". This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a sel...
What is the current status of trial NCT05732831?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 225 participants. The study started on 2023-05-26. Estimated completion is 2026-09.
What conditions does trial NCT05732831 study?
This clinical trial studies the following conditions: Locally Advanced Solid Tumor.
What interventions are being tested in trial NCT05732831?
The interventions under investigation include: Pembrolizumab (DRUG), TNG462 (DRUG).
Who is sponsoring clinical trial NCT05732831?
This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05732831 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05732831's enrollment target sits among peer trials
225 5th of 13 higher than 9 of 13 other Locally Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Locally Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
RECRUITING · Phase 1
-
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
RECRUITING · Phase 1
-
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
RECRUITING · Phase 1
-
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
RECRUITING · Phase 1
-
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI